240 related articles for article (PubMed ID: 23160937)
1. Methylphenidate : a treatment for Parkinson's disease?
Devos D; Moreau C; Delval A; Dujardin K; Defebvre L; Bordet R
CNS Drugs; 2013 Jan; 27(1):1-14. PubMed ID: 23160937
[TBL] [Abstract][Full Text] [Related]
2. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
3. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.
Wagner AK; Drewencki LL; Chen X; Santos FR; Khan AS; Harun R; Torres GE; Michael AC; Dixon CE
J Neurochem; 2009 Feb; 108(4):986-97. PubMed ID: 19077052
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
6. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
[TBL] [Abstract][Full Text] [Related]
7. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Devos D; Krystkowiak P; Clement F; Dujardin K; Cottencin O; Waucquier N; Ajebbar K; Thielemans B; Kroumova M; Duhamel A; Destée A; Bordet R; Defebvre L
J Neurol Neurosurg Psychiatry; 2007 May; 78(5):470-5. PubMed ID: 17098845
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
[TBL] [Abstract][Full Text] [Related]
11. The dopamine transporter: importance in Parkinson's disease.
Nutt JG; Carter JH; Sexton GJ
Ann Neurol; 2004 Jun; 55(6):766-73. PubMed ID: 15174010
[TBL] [Abstract][Full Text] [Related]
12. Gait and attentional performance in freezers under methylphenidate.
Delval A; Moreau C; Bleuse S; Guehl D; Bestaven E; Guillaud E; Dujardin K; Defebvre L; Devos D
Gait Posture; 2015 Feb; 41(2):384-8. PubMed ID: 25468682
[TBL] [Abstract][Full Text] [Related]
13. Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.
Schrantee A; Tremoleda JL; Wylezinska-Arridge M; Bouet V; Hesseling P; Meerhoff GF; de Bruin KM; Koeleman J; Freret T; Boulouard M; Desfosses E; Galineau L; Gozzi A; Dauphin F; Gsell W; Booij J; Lucassen PJ; Reneman L
PLoS One; 2017; 12(2):e0172776. PubMed ID: 28241065
[TBL] [Abstract][Full Text] [Related]
14. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.
Dresel S; Krause J; Krause KH; LaFougere C; Brinkbäumer K; Kung HF; Hahn K; Tatsch K
Eur J Nucl Med; 2000 Oct; 27(10):1518-24. PubMed ID: 11083541
[TBL] [Abstract][Full Text] [Related]
15. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.
Santangelo G; Vitale C; Picillo M; Cuoco S; Moccia M; Pezzella D; Erro R; Longo K; Vicidomini C; Pellecchia MT; Amboni M; Brunetti A; Salvatore M; Barone P; Pappatà S
Parkinsonism Relat Disord; 2015 May; 21(5):489-93. PubMed ID: 25753457
[TBL] [Abstract][Full Text] [Related]
16. Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics.
Wooters TE; Bardo MT; Dwoskin LP; Midde NM; Gomez AM; Mactutus CF; Booze RM; Zhu J
Behav Brain Res; 2011 May; 219(1):98-107. PubMed ID: 21219939
[TBL] [Abstract][Full Text] [Related]
17. Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
Mito Y; Yabe I; Yaguchi H; Sato C; Takei T; Terae S; Tajima Y
Clin Neurol Neurosurg; 2020 Sep; 196():105960. PubMed ID: 32593043
[TBL] [Abstract][Full Text] [Related]
18. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
[TBL] [Abstract][Full Text] [Related]
19. Long Withdrawal of Methylphenidate Induces a Differential Response of the Dopaminergic System and Increases Sensitivity to Cocaine in the Prefrontal Cortex of Spontaneously Hypertensive Rats.
dos Santos Pereira M; Sathler MF; Valli Tda R; Marques RS; Ventura AL; Peccinalli NR; Fraga MC; Manhães AC; Kubrusly R
PLoS One; 2015; 10(10):e0141249. PubMed ID: 26509840
[TBL] [Abstract][Full Text] [Related]
20. Consequences of Acute or Chronic Methylphenidate Exposure Using Ex Vivo Neurochemistry and In Vivo Electrophysiology in the Prefrontal Cortex and Striatum of Rats.
Di Miceli M; Derf A; Gronier B
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
